Table 1 Technical, regulatory and score cell type for PD-L1 clones
From: Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
| Commercial diagnostic assays used in clinical studies | ||||
|---|---|---|---|---|
| Clone | SP142 | SP263 | 22C3 | 28–8 |
| Binding epitope | Cytoplasmic domain | Discontinuous segments in the extracellular domain | ||
| Platform | Ventana BenchMark ULTRA | Agilent Link 48 | ||
| Partner drug | Atezolizumab | Durvalumab | Pembrolizumab | Nivolumab |
| Drug regulatory situationa | Approved | Not approved | Not approved | Not approved |